Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Erasca, Inc. before investing.

In this article, we go over a few key elements for understanding Erasca, Inc.’s stock price such as:

• Erasca, Inc.’s current stock price and volume
• Why Erasca, Inc.’s stock price changed recently
• Upgrades and downgrades for ERAS from analysts
• ERAS’s stock price momentum as measured by its relative strength

About Erasca, Inc. (ERAS)

Before we jump into Erasca, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Want to learn more about Erasca, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Erasca, Inc..

Erasca, Inc.’s Stock Price as of Market Close

As of December 02, 2025, 4:00 PM, CST, Erasca, Inc.’s stock price was $2.890.

Erasca, Inc. is down 3.67% from its previous closing price of $3.000.

During the last market session, Erasca, Inc.’s stock traded between $2.875 and $3.040. Currently, there are approximately 283.68 million shares outstanding for Erasca, Inc..

Erasca, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Erasca, Inc. Stock Price History

Erasca, Inc.’s (ERAS) price is currently down 8.83% so far this month.

During the month of December, Erasca, Inc.’s stock price has reached a high of $3.180 and a low of $2.875.

Over the last year, Erasca, Inc. has hit prices as high as $3.300 and as low as $1.010. Year to date, Erasca, Inc.’s stock is up 15.14%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Erasca, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there was 1 analyst who downgraded Erasca, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Erasca, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Erasca, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Erasca, Inc. (ERAS) by visiting AAII Stock Evaluator.

Relative Price Strength of Erasca, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Erasca, Inc. has a weighted four-quarter relative price strength of 26.43%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Erasca, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Erasca, Inc. Stock Price: Bottom Line

As of December 2, 2025, Erasca, Inc.’s stock price is $2.890, which is down 3.67% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Erasca, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.